Rosai–Dorfman–Destombes disease of the nervous system: A systematic literature review Review
| Authors: | Nasany, R. A.; Reiner, A. S.; Francis, J. H.; Abla, O.; Panageas, K. S.; Diamond, E. L. |
| Review Title: | Rosai–Dorfman–Destombes disease of the nervous system: A systematic literature review |
| Abstract: | Background: Rosai–Dorfman–Destombes disease (RDD) is a rare histiocytic disorder with heterogeneous clinical manifestations and rare neurologic involvement. The existing clinical literature about neurologic RDD has yet to be critically examined. Methods: We performed a four-database English-language systematic literature search for cases of RDD neurohistiocytosis, excluding secondary literature. Individual patient data for neurologic symptoms, disease sites, treatments, and responses were captured. Responses to first-line and second-line surgical interventions, post-surgical radiotherapy, and systemic therapies were analyzed. Results: Among 4769 articles yielded by literature search, 154 articles were fully reviewed, containing data on 224 patients with neurologic RDD. 128 (83.1%) articles were single case reports. 149 (66.5%) patients were male, 74 (33.5%) female, with a median age of 37.6 years (range 2–79). Presenting neurologic symptoms included headache (45.1%), focal neurological deficits (32.6%), visual symptoms (32.1%), and seizures (24.6%). RDD involvement was multifocal in 32 (14.3%) cases. First-line treatment involved resection in 200 (89.6%) patients, with subsequent progression in 52 (26%), including 41 (78.8%) with unifocal disease. No difference was observed in progression-free survival comparing post-operative radiotherapy to no radiotherapy following partial resection. Chemotherapy given alone as first-line treatment led to complete or partial response in 3/7(43%) patients. Second-line treatments led to complete or partial response in 18/37(37.5%) patients. Mutational data were reported on 10 patients (4.46%). Conclusions: This review highlights the limited published data about neurologic RDD, which presents with varied symptomatology and outcome. Further study is needed about its mutational landscape, and more effective therapies are needed for recurrent and refractory disease. © 2022, The Author(s). |
| Keywords: | mitogen activated protein kinase; adolescent; adult; cancer survival; child; controlled study; aged; major clinical study; somatic mutation; clinical feature; chemotherapy; cytarabine; methotrexate; temozolomide; progression free survival; etoposide; cyclophosphamide; melphalan; steroid; vincristine; mutational analysis; vinblastine; hypothalamus hypophysis system; systematic review; protein s 100; immunophenotyping; cognitive defect; sex difference; headache; symptomatology; age distribution; histiocytosis; clofarabine; cladribine; mercaptopurine; cd68 antigen; disease registry; mapk pathway; human; male; female; article; sinus histiocytosis; rosai–dorfman disease |
| Journal Title: | Orphanet Journal of Rare Diseases |
| Volume: | 17 |
| ISSN: | 1750-1172 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2022-03-02 |
| Start Page: | 92 |
| Language: | English |
| DOI: | 10.1186/s13023-022-02220-0 |
| PUBMED: | 35236371 |
| PROVIDER: | scopus |
| PMCID: | PMC8889645 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 April 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work